At a Glance
- Company: Beckman Coulter Life Sciences; Automata
- Location: Global (Beckman: Indianapolis; Automata: London)
- Headline: Strategic partnership; part of Danaher Ventures’ Series C investment in Automata
- Focus area: Modular, AI‑ready lab automation for life sciences
- Next steps: Broader integration into LINQ ecosystem and showcase at SLAS 2026
What happened?
Beckman Coulter Life Sciences and Automata have formed a strategic partnership to bring modular, AI‑ready lab automation to scientists worldwide. The collaboration integrates Beckman Coulter’s liquid handling, genomic and cell‑analysis instruments into Automata’s LINQ automation ecosystem, enabling faster, more consistent and scalable experimentation in research labs.
Why does it matter?
Manual, fragmented workflows remain a bottleneck in discovery and development. By combining Beckman Coulter’s trusted instruments with Automata’s cloud‑native orchestration and modular robotics, the partnership aims to increase throughput, improve data integrity and create “AI‑ready” environments where structured, high‑quality datasets can feed into machine‑learning models and agentic‑AI tools.
Who’s behind it?
Beckman Coulter Life Sciences, a Danaher Corporation company, is a global leader in laboratory automation and life‑science tools. Automata is a London‑based lab‑automation firm building fully integrated, AI‑ready platforms for life‑science R&D; its LINQ platform unifies instruments, robotics and scheduling software into programmable work cells. Danaher Ventures is also participating in Automata’s Series C round and joining its board, reinforcing the strategic alignment.
How was it achieved?
The partnership embeds Beckman Coulter instruments into Automata’s LINQ platform, which uses intelligent robotics and a unified scheduling engine to standardise and automate multistep workflows. LINQ’s workflow‑design environment lets scientists configure modular work cells for specific applications, while its cloud‑native orchestration generates structured data streams that are well suited for AI‑driven analysis and simulation.
What’s next?
Life‑science organisations are expected to adopt the combined solution to accelerate screening, assay development and routine testing. Additional integration details and use cases will be highlighted at the Society for Laboratory Automation and Screening (SLAS) Annual Meeting in February 2026, where Beckman Coulter and Automata will showcase expanded automation options and joint workflows.
What are people saying?
Joe Fox, President of Beckman Coulter Life Sciences, said the partnership reflects a focus on empowering scientists to translate ideas into impact faster, noting that “agentic AI is poised to transform the way wet‑lab screening studies are performed.” Automata emphasises that its platform is designed to let scientists “program experiments rather than robots,” turning the physical lab into a programmable, repeatable system for AI‑driven discovery.